LY294002联合AD-PTEN对脑胶质瘤细胞增殖和侵袭的影响及机制探讨

目的观察P13K抑制剂LY294002联合含VIEN基因的重组腺病毒（Ad—PTEN）对人脑胶质瘤TJ899细胞增殖和侵袭的影响,并探讨其机制。方法向TJ889分别加入LY294002（LY294002组）、Ad-PTEN＋LY294002（联合组）、Ad—vector病毒（空载组）、DMSO（DMSO组）培养48h。分别采用MTY法、流式细胞术、划痕实验和Tran．swell小室观察TJ899增殖活性和侵袭能力的变化;Western Blot检测TJ899的PTEN／P13K／AKT信号转导通路中相关蛋白。结果与DMSO组、空载组和LY294002组相比,联合组细胞存活速率下降,细胞周期阻滞在G0／G1期,S期减少,细胞凋亡率增加,侵袭和迁移的细胞数减少,PTEN蛋白表达增加,而磷酸化蛋白激酶B、细胞增殖抗原、细胞周期素D1、Bcl-2、基质金属蛋白酶-2、黏着斑激酶蛋白表达显著下降,P均〈0．05。结论LY294002联合Ad-PTEN可明显抑制TJ899的增殖活性和侵袭能力,该作用与抑制P13K／AKT信号通路有关。     

过表达miR-150通过PI3K/AKT信号通路调控结直肠癌细胞凋亡的机制研究

目的探讨过表达miR-150通过磷脂酰肌醇-3-羟激酶/丝苏氨酸蛋白激酶(phosphatidylinositol 3-hydroxykinase/seronine kinase,PI3K/AKT)信号通路调控结直肠癌细胞凋亡的机制。方法将体外培养HT-29细胞分为空白对照组(转染空脂质体) NC组(转染mimic)和miR-150(转染miR-150 mimic);采用RT-PCR检测转染后细胞中miR-150 mRNA水平; CCK-8法检测细胞增殖;流式细胞仪检测细胞凋亡; WB法检测Cleaved caspase3、PI3K、p-PI3K、AKT、p-AKT蛋白表达。将对数生长期HT-29分为阴性对照组、miR-150组、LY294002组和LY294002+miR-150组,采用PI3K抑制剂验证LY294002在HT-29细胞凋亡中的作用。结果与空白对照组和NC组相比,miR-150组细胞中miR-150 mRNA水平明显升高(P 0. 05),24 h、48 h、72 h和96h的细胞抑制率明显升高(P 0. 05),细胞凋亡率明显升高(P 0. 05),Bcl-2/Bax、p-PI3K/PI3K和p-Akt/Akt蛋白的表达明显降低(P 0. 05),cleaved Caspase-3蛋白的表达明显升高(P 0. 05);与阴性对照组相比,miR-150组和LY294002组p-Akt/Akt和Bcl-2/Bax蛋白表达均明显降低(P 0. 05),cleaved Caspase-3蛋白表达明显升高(P 0. 05);与miR-150组相比,LY294002+miR-150组p-Akt/Akt和Bcl-2/Bax蛋白表达均明显升高(P 0. 05),cleaved Caspase-3蛋白表达明显降低(P 0. 05)。结论 miR-150过表达可能通过负调控PI3K/AKT信号通路抑制人结直肠癌细胞的增殖,促进其凋亡。     

肺癌中PI3K／AKT信号通路对Skp2调控机制的研究

目的探讨肺癌中磷脂酰肌醇-3-激酶（P13K）／AKT信号通路对S期激酶相关蛋白2（Skp2）的调控机制。方法体外培养4种类型肺癌细胞系H460、LK2、H446和A549,经LY294002处理细胞24h后实时RT—PCR法检测Skp2基因表达变化;Westernblot检测E2F1蛋白表达变化。结果实时RT—PCR显示LY294002作用后4种肺肿瘤细胞系中skp2基因表达均下降;Westernblot结果表明在小细胞肺癌、肺鳞癌、大细胞肺癌中E2F1蛋白表达降低,肺腺癌中E2F1蛋白未表达。结论肺癌中P13K／AKT通路可在转录水平调节Skp2表达,在小细胞肺癌、肺鳞癌、大细胞肺癌中此种调节可能通过转录因子E2F1发挥作用,而肺腺癌中E2F1不参与此种调节。     

PI3K／Akt信号转导通路阻断剂对卵巢癌细胞顺铂敏感性的影响

目的 探讨磷脂酰肌醇3-激酶／丝氨酸-苏氨酸蛋白激酶（P13K／Akt）信号转导通路阻断剂LY294002对卵巢癌细胞顺铂（DDP）敏感性的影响。方法DDP和LY294002单独或联合作用人卵巢癌细胞,MTT法检测细胞生长抑制率,倒置显微镜观察凋亡细胞形态,流式细胞术检测凋亡细胞。结果加用LY294002后,DDP对卵巢癌细胞的抑制作用增强,细胞凋亡率上升。结论PI3K／AKt信号转导通路阻断剂可有效提高卵巢癌细胞对DDP的敏感性,在卵巢癌治疗中与DDP有一定协同作用。     

阻断PI3K/Akt通路增强缺氧环境胰腺癌细胞化疗敏感性的实验研究

目的研究LY294002联合吉西他滨是否能增强缺氧环境下胰腺癌细胞株PANC-1的化疗敏感性。方法缺氧条件下培养胰腺癌细胞株PANC-1,运用MTT检测LY294002联合吉西他滨对胰腺癌细胞株细胞PANC-1生长的影响,运用Western blot检测AKT及磷酸化AKT蛋白表达的水平。结果 MTT检测在缺氧环境下LY294002联合吉西他滨作用的胰腺癌细胞PANC-1与单纯吉西他滨作用组相比细胞生存率显著下降(P=0.003),且具有时间依赖性。Western blot检测显示在缺氧环境下,LY294002联合吉西他滨作用的胰腺癌细胞PANC-1磷酸化AKT蛋白水平与单纯吉西他滨作用组相比显著降低(P=0.002)。结论阻断PI3K/Akt通路能增强缺氧环境下胰腺癌细胞化疗敏感性,为胰腺癌的治疗方法及逆转耐药提供了新的实验依据。     

活性维生素D3联合LY294002体外抑制大鼠肝星状细胞增殖作用研究

目的探究维生素D的活性形式—1,25-(OH)2D3联合磷脂酰肌醇-3激酶/蛋白激酶B(PI3K/Akt)信号通路的特异抑制剂LY294002对体外培养大鼠肝星状细胞的抑制作用。方法将HSC-T6细胞分为正常对照、DMSO组、1,25-(OH)2D3、LY294002组和1,25-(OH)2D3+LY294002联合组,采用MTT法检测细胞增殖;在倒置显微镜下观察细胞形态变化;使用流式细胞术检测HSC-T6细胞凋亡;采用Western blotting法检测Phospho-Akt(Ser473)、AKT(PAN)、半胱氨酸天冬氨酸蛋白酶(caspase)-3蛋白表达。结果体外干预肝星状细胞48 h后,两药联合干预组细胞抑制率为87.5%,显著高于1,25-(OH)2D3组的50.3%或LY294002组的40.3%(P0.05);联合组细胞凋亡率为92.12%,显著高于1,25-(OH)2D3组的71.0%或LY294002组的34.0%(P0.05);在显微镜下观察,两药处理组细胞形状由星形变为不规则形,凋亡数量增多,表现为正常活细胞数目明显减少,胞间隙增宽,细胞体积缩小,胞浆浓缩,胞核固缩,可见空泡及细胞碎片,有的细胞出现数量不等的凋亡小体;与单药干预组比,联合组细胞Bax/Bcl-2比值上升明显(P0.05),活化的凋亡蛋白caspase-3表达显著增加(P0.05)。结论 1,25-(OH)2D3可协同LY294002共同诱导HSC-T6细胞凋亡,增强其抗肝纤维化的效果。     

磷脂酰肌醇3-激酶/蛋白激酶B信号通路对CD40介导胃癌细胞侵袭与转移的研究

目的 探讨可溶性CD40配体(sCD40L)联合磷脂酰肌醇3-激酶/蛋白激酶B(P13K/Akt)信号通路特异性阻断剂LY294002对胃癌AGS细胞体外增殖及侵袭、转移的影响;初步探讨其可能的作用机制.方法 将细胞分成对照组(仅加入含10%胎牛血清的RPMI 1640培养液)、LY294002组(20μmol/L)、sCD40L组(2μg/ml)和LY294002+sCD40L组.四甲基偶氮唑盐法检测不同浓度sCD401,及联合LY294002对细胞增殖的影响;Transwell实验和划痕实验分析细胞侵袭、转移能力的改变;Western印迹检测细胞P13K、p-Akt、血管内皮生长因子(VEGF)蛋白表达的变化.结果 LY294002作用后细胞生存率为65.7%,sCD40L作用后为70.1%,LY294002+sCD40L组生存率为41.3 0A,差异有统计学意义(P<0.05).LY294002+sCD40L组细胞的划痕愈合速度较sCD40L和LY294002组明显减慢.LY294002+sCD40L组平均每个视野的细胞数较sCD40L和LY294002组明显减少.与对照组相比,sCD40L使P13K、p-Akt、VEGF蛋白表达升高,与LY294002联合作用后,P13K,p-Akt、VEGF蛋白表达明显降低.结论 阻断P13K/Akt信号途径可显著增强sCD40L对人胃癌AGS细胞增殖及侵袭、转移的抑制作用,为胃癌的生物治疗提供一种新的方法.     

活性维生素D3联合LY294002体外抑制大鼠肝星状细胞增殖作用研究*

目的探究维生素D的活性形式—1,25-(OH）2D3联合磷脂酰肌醇-3激酶/蛋白激酶B(PI3K/Akt）信号通路的特异抑制剂LY294002对体外培养大鼠肝星状细胞的抑制作用。方法将HSC-T6细胞分为正常对照、 DMSO组、1,25-(OH）2D3、LY294002组和1,25-(OH）2D3+ LY294002 联合组,采用MTT法检测细胞增殖;在倒置显微镜下观察细胞形态变化;使用流式细胞术检测HSC-T6细胞凋亡;采用Western blotting法检测Phospho-Akt（Ser473）、AKT（PAN）、半胱氨酸天冬氨酸蛋白酶（caspase）-3蛋白表达。结果体外干预肝星状细胞48 h后,两药联合干预组细胞抑制率为87.5%,显著高于1,25-（OH）2D3组的50.3%或LY294002组的40.3%（P<0.05）;联合组细胞凋亡率为92.12%,显著高于1,25-(OH）2D3组的71.0%或LY294002组的34.0%（P<0.05）;在显微镜下观察,两药处理组细胞形状由星形变为不规则形,凋亡数量增多,表现为正常活细胞数目明显减少,胞间隙增宽,细胞体积缩小,胞浆浓缩,胞核固缩,可见空泡及细胞碎片,有的细胞出现数量不等的凋亡小体;与单药干预组比,联合组细胞Bax/Bcl-2比值上升明显（P<0.05）,活化的凋亡蛋白caspase-3表达显著增加（P<0.05）。结论1,25-（OH）2D3可协同LY294002 共同诱导 HSC-T6 细胞凋亡,增强其抗肝纤维化的效果。     

异丙酚对过氧化氢导致PCI2细胞损伤的影响及机制

目的探讨异丙酚对过氧化氢（H2O2）导致的PCI2细胞损伤的影响及机制。方法以H2O2损伤PCI2细胞作为氧化应激细胞损伤模型,加入10μmol／L的异丙酚,采用MTF法分析细胞存活率,Hoechst33258染色检测细胞核形态变化,罗丹明123染色检测细胞线粒体膜电位变化,双氯荧光黄乙酸乙酯（DCF—DA）染色检测细胞内活性氧（ROS）的含量,免疫印迹法检测pAkt蛋白表达;在此基础上,探讨异丙酚保护作用机制时再加入LY294002,分别检测细胞上述指标及pAkt的表达。结果H2O2可致PCI2细胞存活率下降,凋亡增加,异丙酚（10μmol／L）可使PCI2细胞的存活率增加,凋亡率降低;异丙酚可抑制H2O2导致ROS和膜电位变化;增加Akt磷酸化水平;P13K抑制剂LY294002可拮抗异丙酚的保护作用,使细胞存活率降低、ROS生成增加、膜电位下降。结论异丙酚可减轻H2O2导致的PCI2细胞损伤,这一作用是通过激活P13K／Akt通路实现的。     

弓形虫ROP16蛋白对人乳腺癌MCF-7细胞增殖、周期和凋亡的影响

目的 探讨弓形虫Ⅰ型(RH)ROP16蛋白在人乳腺癌MCF-7细胞增殖、周期及凋亡方面的作用。方法 以空载体(MCF-7-HBLV)和过表达ROP16蛋白的慢病毒(HBLV-RH ROP16)分别感染MCF-7细胞,嘌呤霉素筛选出稳定表达ROP16的细胞株,Real time PCR、Western blot法检测MCF-7细胞中ROP16 mRNA和蛋白表达水平。CCK-8和流式细胞术检测细胞增殖、周期和凋亡。Western blot法检测细胞周期及凋亡相关蛋白表达。结果 相比MCF-7-HBLV(空载体组)和MCF-7细胞组(对照组),MCF-7-RH ROP16细胞组中ROP16 mRNA和蛋白表达升高;细胞增殖率降低(P<0.01);S期细胞比例、细胞凋亡率升高(P<0.01)。促凋亡因子Bax、P53、Caspase-9、Caspase-3及细胞周期蛋白依赖激酶抑制因子P21表达增高(P<0.01);抗凋亡蛋白Bcl-2及细胞周期蛋白A1(CyclinA1)、周期蛋白依赖性激酶2(CDK2)的表达均下降(P<0.01)。结论 弓形虫Ⅰ型(RH)ROP1...     

Enhanced sensitivity to rapamycin following long-term oestrogen deprivation in MCF-7, T-47-D and ZR-75-1 human breast cancer cells

Human breast cancer cells (MCF-7, T-47-D and ZR-75-1) can adapt to circumvent any reduced growth rate during long-term oestrogen deprivation, and this provides three model systems to investigate mechanisms of endocrine resistance in breast cancer. In this paper we report consistent differences in the effects of three growth inhibitors following long-term oestrogen deprivation in all three cell models. Long-term oestrogen deprivation of MCF-7, T-47-D and ZR-75-1 cells resulted in reduced growth inhibition by PD98059 (2-10 μg/ml), implying a loss of dependence on mitogen-activated protein kinase pathways for growth. The growth inhibitor LY294002 (2-10 μM) inhibited growth of both oestrogen-maintained and oestrogen-deprived cells with similar dose-responses, implying continued similar dependence on phosphoinositide 3-kinase (PI3K) pathways with no alteration after adaptation to oestrogen independent growth. However, by contrast, long-term oestrogen deprivation resulted in an increased sensitivity to growth inhibition by rapamycin, which was not reduced by readdition of oestradiol. The enhanced inhibition of long-term oestrogen-deprived MCF-7-ED, T-47-D-ED and ZR-75-1-ED cell growth by combining rapamycin with LY294002 at concentrations where each alone had little effect, offers preclinical support to the development of therapeutic combinations of rapamycin analogues with other PI3K inhibitors in endocrine-resistant breast cancer.     

Protein kinase C (PKC)-delta/-epsilon mediate the PKC/Akt-dependent phosphorylation of extracellular signal-regulated kinases 1 and 2 in MCF-7 cells stimulated by bradykinin

In this paper the signal transduction pathways evoked by bradykinin (BK) in MCF-7 breast cancer cells were investigated. BK activation of the B(2) receptor provoked: (a) the phosphorylation of the extracellular signal-regulated kinases 1 and 2 (ERK1/2); (b) the translocation from the cytosol to the membrane of the conventional protein kinase C-alpha (PKC-alpha) and novel PKC-delta and PKC-epsilon; (c) the phosphorylation of protein kinase B (PKB/ Akt); (d) the proliferation of MCF-7 cells. The BK-induced ERK1/2 phosphorylation was completely blocked by PD98059 (an inhibitor of the mitogen-activated protein kinase kinase (MAPKK or MEK)) and by LY294002 (an inhibitor of phosphoinositide 3-kinase (PI3K)), and was reduced by GF109203X (an inhibitor of both novel and conventional PKCs); G?6976, a conventional PKCs inhibitor, did not have any effect. The BK-induced phosphorylation of PKB/Akt was blocked by LY294002 but not by PD98059. Furthermore, LY294002 inhibited the BK-provoked translocation of PKC-delta and PKC-epsilon suggesting that PI3K may be upstream to PKCs. Finally, the proliferative effects of BK were blocked by PD98059, GF109203X and LY294002. These observations demonstrate that BK acts as a proliferative agent in MCF-7 cells activating intracellular pathways involving novel PKC-delta/-epsilon, PKB/Akt and ERK1/2.     

PTEN对乳腺癌多药耐药MCF-7/ADR细胞凋亡的促进作用及机制

目的观察野生型PTEN基因促进乳腺癌多药耐药细胞MCF-7/ADR凋亡的作用并探讨其机制。方法采用脂质体介导法将真核表达载体pEGFP-C1-PTEN及突变载体pEGFP-C1-PTEN-C124S转染人乳腺癌多药耐药MCF-7/ADR细胞。MTT法观察细胞对阿霉素的敏感性和耐药倍数,流式细胞技术检测细胞凋亡率,Western blot检测Bcl-2和Caspase-3蛋白。结果转染组的凋亡率为36.86%,高于对照组（3.75%）和C124S组（4.00%）（P均〈0.05）。转染组对阿霉素的耐药倍数显著降低（t=4.77,P〈0.05）,其半数致死剂量IC50值为对照组的26.1%。转染后细胞内Bcl-2表达降低,且检测到Caspase-3活性裂解片段。结论PTEN基因可能通过下调Bcl-2表达及活化Caspase-3来促进乳腺癌多药耐药MCF-7/ADR细胞凋亡,增加其对阿霉素的药敏性。     

PI3K抑制剂LY294002对人晶状体上皮细胞E2F-1、cyclinE蛋白表达的影响

目的探讨PI3K抑制剂LY294002对人晶状体上皮细胞（LECs）增殖及E2F-1、细胞周期素E（cyclinE）蛋白表达的影响。方法人LECs常规培养,分为实验组和对照组,实验组加入PI3K抑制剂LY294002（25μmol/L）,对照组加入同体积DMSO,两组分别培养36 h后,MTT比色法测定细胞增殖状况,Western blot法检测细胞中E2F-1及cyclinE蛋白表达。结果实验组细胞增殖受到明显抑制,与对照组比较差异有统计学意义（P〈0.05）,人LECs中E2F-1及cyclinE蛋白表达降低（P〈0.05）。结论 PI3K抑制剂LY294002可抑制人LECs的增殖,可能与下调E2F-1及cyclinE蛋白的表达水平相关。     

Loss of PTEN function may account for reduced proliferation pathway sensitivity to LY294002 in human prostate and bladder cancer cells

Purpose  Inhibition of phosphoinositide 3 (PI3)-kinase pathway is attractive for cancer treatment. To examine the role of the phosphatase and tensin homolog (PTEN) in the development of resistance to the treatment. Methods  We cultured human prostate cancer cells (DU145 and PC-3 cells) and bladder cancer cells (EJ-1 and UM-UC-3 cells) with a PI3-kinase inhibitor, LY294002 for more than 6 weeks and cell proliferation was studied. Activation of Akt1 and ERK was examined by immunoblotting. We introduced the wild type PTEN in UM-UC-3 cells and their proliferation along with the signaling pathways was also examined. Results  After 6 weeks, proliferation pathway sensitivity to LY294002 was reduced in cells expressing PTEN, but not in PTEN-null cells. PD98059, a MAPK/ERK kinase inhibitor, significantly inhibited proliferation of PTEN-expressing cells, but not PTEN-null cells. Stable PTEN expression in PTEN-null UM-UC-3 cells increased serum-induced ERK activation and sensitivity to PD98059-treatment, and reduced sensitivity to LY294002 after 6 weeks of exposure. Conclusions  Loss of PTEN function may protect against resistance to PI3-kinase inhibitors through an addiction to the PI3-kinase/Akt pathway.     

PI3K/Akt抑制剂LY294002对胃癌细胞化疗增敏作用的探讨

目的 探讨PI3K/Akt特异性抑制剂LY294002与化疗药物5-Fu及奥沙利铂联合使用对3种胃癌细胞系(MGC803、BGC823和SGC7901)化疗效果的影响.方法 将PI3K/Akt特异性抑制剂LY294002联合化疗药物5-Fu及奥沙利铂作用于3种胃癌细胞系,MTT法检测单独使用5-Fu、奥沙利铂及联合LY294002对体外培养的3种胃癌细胞系的增殖抑制作用,流式细胞术检测细胞凋亡.结果 联合LY294002作用后,5-Fu、奥沙利铂对3种胃癌细胞系的增殖抑制作用明显增强(P<0.05),且凋亡率显著提高(P<0.05).结论结果 LY294002能有效提高化疗药物5-Fu、奥沙利铂体外对胃癌细胞的增殖抑制作用,抑制PI3K/Akt信号转导通路可显著提高胃癌的化疗疗效.